Livzon Pharmaceutical Group Management

Management criteria checks 4/4

Livzon Pharmaceutical Group's CEO is Yanggang Tang, appointed in Dec 2018, has a tenure of 5.92 years. total yearly compensation is CN¥581.00K, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 0.038% of the company’s shares, worth CN¥11.27M. The average tenure of the management team and the board of directors is 10.4 years and 6.6 years respectively.

Key information

Yanggang Tang

Chief executive officer

CN¥581.0k

Total compensation

CEO salary percentage	19.1%
CEO tenure	5.9yrs
CEO ownership	0.04%
Management average tenure	10.4yrs
Board average tenure	6.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Yanggang Tang's remuneration changed compared to Livzon Pharmaceutical Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	CN¥2b
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥581k	CN¥111k	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥520k	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Jan 01 2022	n/a	n/a	CN¥2b
Sep 30 2021	n/a	n/a	CN¥2b
Jun 30 2021	n/a	n/a	CN¥2b
Mar 31 2021	n/a	n/a	CN¥2b
Jan 01 2021	n/a	n/a	CN¥2b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥2b
Mar 31 2020	n/a	n/a	CN¥1b
Jan 01 2020	n/a	n/a	CN¥1b
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥3m	CN¥800k	CN¥1b

Compensation vs Market: Yanggang's total compensation ($USD80.26K) is below average for companies of similar size in the CN market ($USD210.05K).

Compensation vs Earnings: Yanggang's compensation has been consistent with company performance over the past year.

CEO

Yanggang Tang (54 yo)

5.9yrs

Tenure

CN¥581,000

Compensation

Mr. Yanggang Tang has been President of Livzon Pharmaceutical Group since December 28, 2018 and serves as its Executive Director since February 14, 2019 and served as its Executive Vice President from July...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yanggang Tang	President & Executive Director	5.9yrs	CN¥581.00k	0.038% CN¥ 11.3m
Guoxiang Xu	Executive Vice Chairman & VP of Sales	7.4yrs	CN¥547.19k	0.086% CN¥ 25.6m
Yanxia Si	VP & CFO	10.4yrs	CN¥354.39k	0.044% CN¥ 13.2m
Liang Yang	VP, Secretary to the Board & Company Secretary	10.4yrs	CN¥235.72k	0.022% CN¥ 6.6m
Daihong Yang	Vice President	18.5yrs	CN¥371.99k	0.051% CN¥ 15.3m
Yuxuan Huang	Vice President	6.1yrs	CN¥239.24k	0.015% CN¥ 4.4m
Jun Du	Vice President	1.2yrs	CN¥516.55k	0.0055% CN¥ 1.6m
Jianing Liu	Chief Investment Officer & Head of BD Dept.	no data	no data	no data
Jianying Zhuang	Head of Accounting Department	no data	no data	no data
Maolin Wang	Chief Supervisor and GM of Legal & Compliance	23.8yrs	CN¥283.13k	no data
Daping Liu	Vice President	less than a year	no data	no data

10.4yrs

Average Tenure

56yo

Average Age

Experienced Management: 000513's management team is seasoned and experienced (10.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yanggang Tang	President & Executive Director	5.8yrs	CN¥581.00k	0.038% CN¥ 11.3m
Guoxiang Xu	Executive Vice Chairman & VP of Sales	7.4yrs	CN¥547.19k	0.086% CN¥ 25.6m
Maolin Wang	Chief Supervisor and GM of Legal & Compliance	14.8yrs	CN¥283.13k	no data
Qingfeng Qiu	Non-Executive Director	17.6yrs	CN¥9.60k	no data
Baoguo Zhu	Non-Executive Chairman of the Board	22.4yrs	CN¥325.00k	no data
Desheng Tao	Non-Executive Vice Chairman	15.3yrs	CN¥300.00k	0.097% CN¥ 28.8m
Qiusheng Tian	Independent Non-Executive Director	5.1yrs	CN¥12.00k	no data
Hua Bai	Independent Non-Executive Director	4.4yrs	CN¥12.00k	no data
Huamin Huang	Supervisor	11.4yrs	CN¥36.00k	no data
Huiyuan Luo	Independent Non-Executive Director	3.3yrs	CN¥12.00k	no data
Kam Wa Wong	Independent Non-Executive Director	5.1yrs	CN¥12.00k	no data
Lijie Cui	Independent Non-Executive Director	3.3yrs	CN¥12.00k	no data

6.6yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 000513's board of directors are considered experienced (6.6 years average tenure).

Livzon Pharmaceutical Group Management

Management criteria checks 4/4

Key information

Recent management updates

Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.54 (vs CN¥0.50 in 3Q 2023)

Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives the Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. Announces Resignation of Yu Xiong as Director

Investor sentiment improves as stock rises 16%

Livzon Pharmaceutical Group Inc. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.62 (vs CN¥0.60 in 2Q 2023)

Now 21% undervalued after recent price drop

Dividend reduced to CN¥1.35

Livzon Pharmaceutical Group Inc. to Report First Half, 2024 Results on Aug 23, 2024

Livzon Pharmaceutical Group Inc., Annual General Meeting, Jun 14, 2024

Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection

Livzon Pharmaceutical Group Inc. to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings released

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2023 Results on Mar 29, 2024

Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use

Livzon Pharmaceutical Group Inc. (SZSE:000513) announces an Equity Buyback for CNY 600 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.52 in 3Q 2022)

Livzon Pharmaceutical Group Inc. and Shanghai Livzon Pharmaceutical Manufacturing Co., Ltd. Receives Acceptance of the Application for the Registration and Marketing Authorization of Triptorelin Acetate Microspheres for Injection

Second quarter 2023 earnings released: EPS: CN¥0.60 (vs CN¥0.50 in 2Q 2022)

Livzon Pharmaceutical Group Inc. Announces Board Appointments

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) (Tax Included) for 2022, Payable on 04 July 2023

Livzon Pharmaceutical Group Inc. Approves Final Cash Dividend for the Year Ended 31 December 2022, Payable on 31 July 2023

Full year 2022 earnings released

Livzon Pharmaceutical Group Inc. Announces Approval of Drug Marketing Authorisation Submitted by Livzon MABPharm Inc. for the Tocilizumab Injection Atvtia

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.52 (vs CN¥0.41 in 3Q 2021)

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2022 Results on Oct 25, 2022

Second quarter 2022 earnings released: EPS: CN¥0.50 (vs CN¥0.58 in 2Q 2021)

Livzon Pharmaceutical Group Inc. Receives Approval Notice for Supplementary Application for Drug

Livzon Pharmaceutical Group Inc. to Report First Half, 2022 Results on Aug 09, 2022

Livzon Pharmaceutical Announces on Drug Passing Consistency Evaluation for Generics

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2021

Less than half of directors are independent

Livzon Pharmaceutical Group Inc., Annual General Meeting, May 20, 2022

Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended 31 December 2021, Payable on June 24, 2022

Livzon Pharmaceutical Group Inc. to Report Q1, 2022 Results on Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥1.90 (vs CN¥1.83 in FY 2020)

Livzon Pharmaceutical Group Inc. Announces Ordinary Final Dividend for the Year Ended December 31, 2021, Payable on June 24, 2022

Investor sentiment improved over the past week

Livzon Pharmaceutical Group Inc. Obtains Approval Notice for Clinical Trial on Drug from National Medical Products Administration

Third quarter 2021 earnings released: EPS CN¥0.41 (vs CN¥0.44 in 3Q 2020)

Livzon Pharmaceutical Group Inc. Announces Approval Notice for Clinical Trial on A Drug

Second quarter 2021 earnings released: EPS CN¥0.58 (vs CN¥0.64 in 2Q 2020)

Independent Non-Executive Director Zhihua Zheng has left the company

Independent Non-Executive Director Yun Xie has left the company

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2020, Payable on or Before June 25, 2021

Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of share transfer agreement to acquire a 40% stake in Tianjin Tongrentang Group Co., Ltd. from Tianjin Tasly Healthcare Industry Investment Partnership.

New 90-day low: CN¥34.73

Livzon Pharmaceutical Group Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.49

Livzon Pharmaceutical Group Inc. announced that it expects to receive CNY 961.6 million in funding from YF Pharmab Limited

New 90-day low: CN¥42.15

New 90-day low: CN¥46.34

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

Livzon Pharmaceutical Group Inc. to Report Nine Months, 2020 Results on Oct 23, 2020

Earnings released

Livzon Pharmaceutical Group Inc. to Report First Half, 2020 Results on Aug 26, 2020

New 90-day high - CN¥56.12

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age